Zeitungsständer (Symbolbild).
Mittwoch, 07.04.2021 23:05 von | Aufrufe: 165

SHAREHOLDER ALERT: WeissLaw LLP Reminds TPCO, EGOV, GWPH, and CMD Shareholders About Its Ongoing Investigations

Zeitungsständer (Symbolbild). © AdrianHancu / iStock Editorial / Getty Images Plus / Getty Images

PR Newswire

NEW YORK, April 7, 2021 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Tribune Publishing Company (NASDAQ: TPCO)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tribune Publishing Company (NASDAQ: TPCO) in connection with the proposed interested-party acquisition of the company by Alden Global Capital. Under the terms of the agreement, Alden Global Capital will acquire all outstanding shares of TPCO common stock that it does not already own for $17.25 per share in cash. If you own TPCO shares and wish to discuss this investigation or your rights, please call or visit our website: http://www.weisslawllp.com/tpco/

NIC Inc. (NASDAQ: EGOV)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NIC Inc. (NASDAQ: EGOV) in connection with the proposed acquisition of the company by Tyler Technologies Inc. Under the terms of the agreement, the company's shareholders will receive $34.00 in cash for each share of EGOV common stock that they hold. If you own EGOV shares and wish to discuss this investigation or your rights, please call or visit our website: http://www.weisslawllp.com/egov/ 

GW Pharmaceuticals plc (NASDAQ: GWPH)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GW Pharmaceuticals plc (NASDAQ: GWPH) in connection with the proposed acquisition of the company by Jazz Pharmaceuticals Public Limited Company ("Jazz"). Under the terms of the merger agreement, Jazz will acquire GWPH in a mixed cash-and-stock transaction for $220.00 per American Depositary Share ("ADS"), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares. If you own GWPH shares and wish to discuss this investigation or your rights, please call or visit our website: http://www.weisslawllp.com/gwph/


ARIVA.DE Börsen-Geflüster

Cantel Medical Corp. (NYSE: CMD)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cantel Medical Corp. (NYSE: CMD) in connection with the proposed acquisition of the company by STERIS plc ("STERIS"). Under the terms of the agreement, STERIS will acquire CMD in a cash-and-stock transaction, pursuant to which CMD shareholders will receive $16.93 in cash and 0.33787 of a STERIS ordinary share for each CMD share, representing implied per-share merger consideration of approximately $82.65 based upon STERIS' April 6, 2021 closing price of $194.50. If you own CMD shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/cmd/

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-tpco-egov-gwph-and-cmd-shareholders-about-its-ongoing-investigations-301264506.html

SOURCE WeissLaw LLP

Werbung

Mehr Nachrichten zur Nic Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.